For example, the 2018 European Association for the Study of Diabetes (EASD) and American Diabetes Association consensus guidelines recommend a sodium‐glucose cotransporter‐2 (SGLT2) inhibitor or a GLP‐1 RA with proven cardiovascular benefits for patients with clinical cardiovascular disease.15 Here, GLP1R is linked to cardiovascular disorder.